Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to 0.56.

  • Theravance Biopharma's Equity Ratio rose 742.5% to 0.56 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.56, marking a year-over-year increase of 742.5%. This contributed to the annual value of 0.5 for FY2024, which is 1110.43% down from last year.
  • Latest data reveals that Theravance Biopharma reported Equity Ratio of 0.56 as of Q3 2025, which was up 742.5% from 0.53 recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Equity Ratio peaked at 0.73 during Q4 2022, and registered a low of 0.99 during Q1 2021.
  • Over the past 5 years, Theravance Biopharma's median Equity Ratio value was 0.53 (recorded in 2025), while the average stood at 0.11.
  • In the last 5 years, Theravance Biopharma's Equity Ratio crashed by 28139.41% in 2021 and then surged by 18052.3% in 2022.
  • Quarter analysis of 5 years shows Theravance Biopharma's Equity Ratio stood at 0.9 in 2021, then soared by 180.52% to 0.73 in 2022, then decreased by 23.34% to 0.56 in 2023, then decreased by 11.1% to 0.5 in 2024, then rose by 12.99% to 0.56 in 2025.
  • Its Equity Ratio was 0.56 in Q3 2025, compared to 0.53 in Q2 2025 and 0.48 in Q1 2025.